Abstract 301P
Background
Cervical cancer is the most prevalent reproductive malignancy in women worldwide and estimated over 600,000 new cases and 340,000 deaths each year. Concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer. Despite the great improvement this strategy has achieved, nearly 30% of patients will suffer distant metastases and 70% of patients may experience local recurrence. The dominance of Lactobacillus in the vaginal microenvironment of healthy women helps to establish a physiological barrier on the vaginal surface, Microbial biomarkers are effective for predicting the nonresponse for immune checkpoint inhibitor administration. It is intriguing to explore the alteration of vaginal microbial community challenged by chemoradiotherapy, also whether microorganism(s) could be used as biomarkers to predict the responsiveness of chemoradiotherapy.
Methods
A total of 126 patients with IB-IVB cervical cancer who received chemoradiotherapy in our hospital were enrolled in this study. The sampling of vaginal microbiome was carried out as we previously described, both pre- and post-treatment of each patient. Bacterial genomic DNA was extracted and 16S rRNA was sequenced from their vaginal secretions, and the results were analyzed bioinformatically.
Results
We found that the structure and composition of the vaginal microbiome changed significantly before and after radiotherapy, and radiotherapy treatment significantly changed the structure of the microorganisms, destroyed their physiological functions and disrupted the homeostasis of the microbial community. At the same time, we found that the beneficial microbial community in the vaginal microbiome decreased significantly in the relapsing group compared with the non-relapsing group before and after radiotherapy, and the microbial function and community homeostasis were significantly reduced, suggesting an unhealthy vaginal microbiome in the relapsing group.
Conclusions
We have shown that C-reactive protein and disease stage and other factors and biomarkers (such as L. iners) are important factors in predicting the recurrence of cervical cancer patients after radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
Zhejiang medicine and health science and technology project.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract